Nivolumab-induced hypothyroidism: A case report.
10.11817/j.issn.1672-7347.2019.02.016
- Author:
Changsong LIN
1
;
Zi GUO
1
;
Zhaohui MO
1
Author Information
1. Department of Endocrinology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
- Publication Type:Case Reports
- MeSH:
Aged;
Antibodies, Monoclonal;
Female;
Humans;
Hypothyroidism;
chemically induced;
Nivolumab;
adverse effects;
Thyroxine
- From:
Journal of Central South University(Medical Sciences)
2019;44(2):222-224
- CountryChina
- Language:Chinese
-
Abstract:
Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody, which is a new drug for tumor immunotherapy. A 73-year-old female patient with colorectal cancer 3 years after surgery was treated in the Endocrinology Department of Third Xiangya Hospital, Central South University, who developed severe hypothyroidism resulting from treatment with nivolumab. After 4 months treatment of nivolumab, this patient presented with symptoms such as fatigue, dizziness, jaundice and palpebral edema, with decreased levels of FT3 and FT4 and elevated levels of TSH. Subsequently, nivolumab treatment was terminated. This patient's symptoms were relieved and thyroid function returned to normal after thyroxine replacement therapy. The clinical diagnosis was considered to be nivolumab-induced autoimmune thyroid damage, which was an immune-related adverse reaction in the treatment.
